177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer.
von Eyben FE, Singh A, Zhang J, Nipsch K, Meyrick D, Lenzo N, Kairemo K, Joensuu T, Virgolini I, Soydal C, Kulkarni HR, Baum RP.
von Eyben FE, et al.
Oncotarget. 2019 Mar 29;10(25):2451-2461. doi: 10.18632/oncotarget.26789. eCollection 2019 Mar 29.
Oncotarget. 2019.
PMID: 31069008
Free PMC article.